Developing treatments that target the KDM6A-dependent epigenome could narrow the difference in male and female bladder cancer risk by decreasing male bladder cancer risk.239 EGFR is closely related to DNA methylation and ovarian cancer development. Here, KDM6A is linked to urinary bladder cancer.